CSL Behring Marks World Hemophilia Day by Donating IUs of Its Specialty Biotherapeutics for Bleeding Disorders to World Federation of Hemophilia

MONTREAL and KING OF PRUSSIA, Pa. — 13 April 2016

  • More than 1.5 million international units (IUs) of treatments for Hemophilia A and/or von Willebrand Disease shipped in advance of World Hemophilia Day
  • Shipment is a part of CSL Behring’s three year promise to provide more than 10 million IUs of specialty biotherapeutics to World Federation of Hemophilia to treat hemophilia in the developing world
  • Donation demonstrates World Federation of Hemophilia’s World Hemophilia Day message: “Treatment for All is the Vision for All”

“Treatment for All is the Vision for All” is the World Federation of Hemophilia’s (WFH) global message for World Hemophilia Day this year (April 17, 2016). Demonstrating that purpose, the WFH and global biotherapeutics leader CSL Behring announced today that CSL Behring has shipped more than 1.5 million international units (IUs) of its specialty biotherapeutics to treat hemophilia A and/or von Willebrand Disease to the WFH Global Alliance for Progress (GAP) Program and other WFH programs. World Hemophilia Day is promoted by WFH to increase global awareness of hemophilia and other inherited bleeding disorders.

"An estimated 6.9 million people around the world are living with a bleeding disorder. Of these, 75 percent remain undiagnosed and receive inadequate care or no care at all,” said WFH President Alain Weill. “That’s why we established the GAP Program, to advance our mission to improve diagnosis and access to care for the millions of people who have a bleeding disorder yet remain without treatment. CSL Behring supports WFH’s mission in improving diagnosis and treatment access worldwide and we look forward to our continued partnership.”

This shipment is a part of CSL Behring’s promise to provide 10 million IUs of one or more of its products from its broad portfolio of bleeding disorder protein therapies to the WFH over the period of three years, beginning this year. The GAP Program strives to improve the diagnosis and treatment of bleeding disorders in developing countries. In 2009, CSL was the first biotherapeutics leader in the world to make a multiyear promise to WFH to aid the GAP Program with humanitarian aid coagulation factor donations over an extended period of time.

"For a century, CSL has focused on keeping our promises to patients who rely on our life-saving medicines to improve their quality of life and, oftentimes, for life itself,” said Paul Perreault, CEO and Managing Director of CSL Limited. "Since our first promise to provide treatments to WFH’s GAP program in 2009, we have donated more than 15 million IUs of our bleeding disorder treatments to WFH for use in developing countries. The GAP program has made meaningful differences in the lives of people around the world and we are proud of our continued partnership with WFH as we work together to improve treatment access in developing countries.”

About the Global Alliance for Progress Program

The Global Alliance for Progress (GAP) Program is a healthcare development project launched in 2003, now in its Second Decade phase (2013-2022). The overarching goals for the GAP Program will be to increase by 50,000 the worldwide number of people identified/diagnosed with a bleeding disorder, as well as to ensure that 50 percent of those newly diagnosed are from the world’s most impoverished countries. CSL Behring supports the WFH GAP Program as one of the program sponsors.

About the World Federation of Hemophilia

For over 50 years, the World Federation of Hemophilia (WFH), an international not-for-profit organization, has worked to improve the lives of people with hemophilia and other inherited bleeding disorders. Established in 1963, it is a global network of patient organizations in 127 countries and has official recognition from the World Health Organization. Visit WFH online at

About CSL Behring

CSL Behring is a global biotherapeutics leader which is driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL), headquartered in Melbourne, Australia, employs more than 16,000 people with operations in more than 30 countries. For more information visit and follow us on



Sarah Ford
World Federation of Hemophilia
Office: 514-394-2822

Greg Healy
CSL Behring
Office: 610-878-4841
Mobile: 610-906-4564

LinkedIn Twitter Facebook Google+